Challenging the Consensus Statement: Is It Time to Recognise Pharmacological Remission of Type 2 Diabetes?
Diabetes, Obesity and Metabolism · 2026-06 · 28 (6) · 4474-4487
DOI: 10.1111/dom.70674 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 19.03.2026. Verfasst von Cristina Bianchi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine-Metabolic and Transplant Medicine and Surgery Department, University Hospital of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 96 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Plasma glucose and HbA 1c concentrations below the diagnostic threshold for diabetes have been achieved in people with type 2 diabetes (T2DM) in three clinical settings: with intensive weight‐management programs that induce > 10–15 kg bodyweight loss, following bariatric surgery, and during treatment with highly effective glucose‐ and weight‐lowering medications. The current consensus definition of T2DM remission excludes a status of absence of diabetes achieved with concomitant use of glucose‐ and weight‐lowering medications. However, since these treatments can safely achieve HbA 1c and plasma glucose concentrations lower than the ones currently used to define remission, we propose to consider a separate category of diabetes remission mainly achieved and maintained with pharmacological treatment. Our arguments are based on: (1) the similar endocrine mechanisms associated with bariatric surgery and use of GLP‐1 receptor agonists or GIP/GLP‐1 dual receptor agonists, (2) the lack of evidence that the effects of near‐normoglycemic states achieved with lifestyle, surgery or glucose‐ and weight‐lowering medications on long‐term complications differ and (3) the frequent use of these medications in conjunction with both lifestyle interventions and following bariatric surgery. With this proposal, we aim to invite further discussion towards expanding the current narrow definition of T2D remission to include remission during treatment with newer highly effective glucose‐ and weight‐lowering medications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrine-Metabolic and Transplant Medicine and Surgery Department, University Hospital of Pisa, Pisa, Italy.
- Interdisciplinary Research Center 'Health Science', Sant'Anna School of Advanced Studies, Pisa, Italy.
- Division of Metabolism, Endocrinology & Diabetes, Michigan Medicine, Ann Arbor, Michigan, USA.
- Department of Nutritional Sciences, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
- Diabetes, Endocrinology, Metabolism, Section Medical Department I St. Josef-Hospital, Katholisches Klinikum Bochum gGmbH, Ruhr-University-Bochum, Bochum, Germany.
- Institute for Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.
ORCID-Profile: Cristina Bianchi, Stefano Del Prato, Michael A Nauck
Zitieren
APA
Bianchi, C., Del Prato, S., Rothberg, A. E., & Nauck, M. A. (2026). Challenging the Consensus Statement: Is It Time to Recognise Pharmacological Remission of Type 2 Diabetes?. Diabetes, Obesity and Metabolism, 28(6), 4474-4487. https://doi.org/10.1111/dom.70674
Vancouver
Bianchi C, Del Prato S, Rothberg AE, Nauck MA. Challenging the Consensus Statement: Is It Time to Recognise Pharmacological Remission of Type 2 Diabetes?. Diabetes, Obesity and Metabolism. 2026;28(6):4474-4487. doi:10.1111/dom.70674
BibTeX
@article{Bianchi2026,
author = {Bianchi, Cristina and Del Prato, Stefano and Rothberg, Amy E and Nauck, Michael A},
title = {Challenging the Consensus Statement: Is It Time to Recognise Pharmacological Remission of Type 2 Diabetes?},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {6},
pages = {4474--4487},
doi = {10.1111/dom.70674}
}
EUVIMED